Treatment Choices for Acute Canine Otitis Externa in Sweden, Finland and Norway: A Comparative Study With a Focus on Antibiotic Use Authors: Kaisa Saarinen, Ditte Ljungquist, Riitta Seppänen, Mirja Kaimio, Anna‐Maria Andersson Published: 2026 ABSTRACT ABSTRACTBackgroundCanine otitis externa (COE) is one of the most frequently recorded disorders in veterinary practices, making it an important focus for antibiotic stewardship.Hypothesis/ObjectivesTo investigate and compare treatment regimens for acute COE in Finland, Norway and Sweden, with a focus on antibiotic use.Animals1060 dogs with acute COE lasting for ≤ 4 weeks.Materials and MethodsThis was a multicentre cross‐sectional study based on a point prevalence survey conducted among Swedish, Finnish and Norwegian veterinary surgeons within a corporate group during spring 2024. In the survey, each practice had been asked to include the first 20 consecutive cases of acute COE and register information about their diagnostic and therapeutic management.ResultsOverall, antibiotic treatment was used in 18% of cases (190 of 1060 dogs), predominantly topical, with systemic use only reported in six cases. Antibiotic use was significantly higher in Norway (28%) and Finland (29%) than in Sweden (2%; p < 0.001). The most frequently used antibiotic was polymyxin B. Antibiotic treatment was more strongly associated with cytological findings, especially the presence of neutrophils and rods, than with clinical presentation. Overall, glucocorticoid treatment was used in 94% and ear cleaner in 89% of cases, with some differences between countries.Conclusions and Clinical RelevanceIn this study, most acute COE cases were managed with glucocorticoids and ear cleaners without antibiotics. Swedish practices stood out with a notably low antibiotic use of 2%. Our results provide valuable information on antibiotic use for acute COE in three Nordic countries, inspiring future antibiotic stewardship efforts. Introduction Canine otitis externa (COE) is a multifactorial inflammatory disease of the external ear canal and pinnae. The aetiology of COE involves primary and secondary causes with predisposing and perpetuating factors [1]. Two distinct clinical presentations of COE are generally recognised: erythroceruminous COE and suppurative COE [2]. Erythroceruminous COE represents 77%–85% of COE cases and is clinically characterised by an erythematous and pruritic ear [2, 3, 4]. Cytological smears from erythroceruminous COE typically demonstrate Malassezia and/or Staphylococcal bacterial overgrowth [2]. Suppurative COE is less commonly encountered, with a reported incidence of 15%–25% of COE cases [3, 4]. It is typically painful, ulcerative and associated with cytological findings of neutrophils and bacteria, especially Gram‐negative rods [2]. Presently, there are no official international guidelines concerning the treatment of COE. However, different national guidelines and international publications advocate topical and/or systemic glucocorticoids, ear cleaning, and, in certain cases, topical antimicrobial therapy [5, 6, 7, 8, 9, 10]. Optimising the use of antibiotics in animals is one of the main objectives of the World Health Organization's global action plan to combat antimicrobial resistance [11]. To aid this, the European Medicines Agency (EMA) has categorised antibiotics to facilitate prudent use among veterinarians [12]. As COE is one of the most frequently recorded disorders in dogs in primary veterinary care (prevalence 4.5%–13%), it is an imperative and important focus for veterinary antibiotic stewardship [13, 14, 15, 16]. This study aimed to analyse and compare treatment choices for COE in everyday practice in Sweden, Finland and Norway, with a particular focus on antibiotic use. Material and Methods Ethics This article is a summary of a clinical audit conducted for quality improvement purposes within the framework of the infection prevention and control (IPC) programme of the corporate group IVC Evidensia. According to Swedish, Finnish and Norwegian regulations, no ethical approval was required, as this was an anonymous survey that did not interfere with routine veterinary practice [17, 18, 19, 20, 21]. Study Design and Setting This multicentre cross‐sectional study was based on a voluntary point‐prevalence survey conducted in Sweden, Finland and Norway between 15 January and 15 March 2024. The survey was sent out to all Finnish, Swedish and Norwegian companion animal veterinary practices within the corporate group IVC Evidensia. The participating veterinary surgeons included both general practitioners and referral clinicians. However, because participation was anonymous, the collected data did not include information about the individual veterinary surgeons' qualifications. Data Collection Data were collected from the survey forms gathered for the clinical audit. The survey was conducted as follows: 2 months before the start of the survey, practices were asked to participate and instructions and forms were sent out. The practices enrolled in the survey were asked to include the first 20 cases of acute COE between 15 January and 15 March 2024, irrespective of age, sex and breed. Inclusion criteria for the survey were cases of acute COE with a duration of ≤ 4 weeks. Exclusion criteria were previous acute COE treatment within a month before the consultation, suspected or confirmed otitis media/interna, findings of a mass within the ear canal, prominent glandular hyperplasia or foreign bodies. Cases of suspected or confirmed otitis media/interna were defined as dogs presenting with neurological signs, a visibly ruptured tympanic membrane or with an otitis media/interna diagnosis confirmed through diagnostic imaging. During the survey period, each veterinary surgeon filled out the survey form, comprising questions about patient characteristics, clinical signs, clinical findings from the ear canals, previous history of COE, cytological and microbiological analyses, treatments and scheduling of re‐visits (Appendix S1). For the participating practices, the survey was considered completed when 20 dogs with COE had been included or by 15 March, irrespective of how many cases the practice had managed to collect. The practices were requested to report the results to the project team within 2 weeks of the final date of the survey. No specific guidance was provided on how COE cases should be managed in the survey instructions. The corporate group did not restrict treatment choices or the availability of any medicinal substances in these countries. Veterinary surgeons and veterinary practices in these countries are not permitted to profit from the sale of medicines. Veterinary surgeons are therefore free to choose any legally available products, registered for animals and humans according to the cascade. Statistical Methods All statistical analyses were performed using stata 18 (Stata Statistical Software). The variables describing the reporting of clinical findings, the use of cytological evaluation, bacterial culture sampling and treatments were analysed per dog and per ear. Details on specific clinical and cytological findings were analysed per ear. To summarise the data, descriptive statistics were presented. The chi‐squared test was used to compare the previous history of COE and the use of cytological examinations, as well as the overall treatment with antibiotics, glucocorticoids and ear cleaners among the three countries. A Firth's penalised logistic regression model was fitted to explore associations between the independent variables (country, clinical findings and cytological findings) and antibiotic use as the dependent variable. This model was chosen to accommodate for the dependent variable being a binary outcome, and some clinical signs and cytological findings were rare. Initially, all independent variables were included in the model. To improve the regression model, nonsignificant variables were excluded using backward elimination. After fitting the main effects model, we explored all plausible interactions. None of the interactions were statistically significant and therefore not included in the final model. The outcome of the model was presented as odds ratios (OR) with 95% confidence intervals (CI). The preset level of significance was 5% (p < 0.05). Results Study Cohort Of the 149 practices invited to take part in the survey, a total of 113 (76%) participated: 50 of 72 (69%) in Sweden, 41 of 46 (89%) in Finland and 22 of 31 (71%) in Norway. In total, the survey comprised 1065 dogs with acute COE. Five cases were omitted from the study cohort (all from Finland) owing to ongoing treatment for acute COE at the time of the recorded visit. Thus, the final analyses included 1060 dogs (423 in Sweden, 446 in Finland and 191 in Norway), with a median of 11 dogs per practice (range 2–20). Owing to a misunderstanding, eight practices registering a total of 60 dogs accidentally used a pilot version of the survey form. This form did not discriminate clinical signs or findings, analyses and treatment between separate ears on the same dog. Hence, these dogs were omitted from the statistical analyses performed per ear yet were still included in the analyses performed per dog. From the remaining 1000 dogs with detailed information about both ears, we performed analyses per ear, disregarding whether clinical signs and/or veterinary clinical findings were reported for one or both ears. Patient Characteristics and Patient History The median age of the dogs was 3 years (range 3 months to 17 years), with a similar distribution in all three countries. The five most common breed presentations across all the countries were mixed‐breed (22%, n = 233), Labrador retriever (8%, n = 89), poodle (6%, n = 64), golden retriever (4%, n = 40), German shepherd dog (3%, n = 33) and cocker spaniel (3%, n = 31). Almost half of the dogs (49%, 522 of 1060) had a reported history of COE (43% in Sweden [183 of 423], 52% in Finland [232 of 446] and 56% in Norway [107 of 191]), with the occurrence significantly differing between the countries (p = 0.004). In total, 8% (80 of 1060) of the dogs were already on medication relevant to dermatological disorders (lokivetmab, oclacitinib, glucocorticoids, levothyroxine, ciclosporin and allergen immunotherapy): 7% in Sweden (28 of 423), 9% (39 of 446) in Finland and 7% (13 of 191) in Norway. The data did not support further analysis of the previous history or ongoing medications. Clinical Findings on Veterinary Ear Examination Per Dog Analysis Of the 1060 dogs included in the study, 97% (1024 dogs) had clinical findings of COE reported on veterinary ear examination. When both ears were affected, the clinical signs could vary between ears. The remaining 3% (36 dogs) in the cohort had no clinical findings reported in the veterinary ear examination, or the survey form was left blank in that regard. However, all of these 36 dogs had reported clinical signs of COE (e.g., pruritus, pain, discharge). Per Ear Analysis Of the 1000 dogs with information about both ears, 1585 ears had at least one clinical finding of COE. In these ears, the three most common clinical findings, either alone or in combination with other findings, were erythema (85%; 1349 of 1585), ceruminous discharge (69%; 1101 of 1585) and oedema (36%; 571 of 1585). Overall, purulent discharge was a relatively uncommon finding (17%; 272 of 1585). The pattern of clinical findings was similar for all three countries. Tables 1, 2, 3 summarise the top three clinical findings per country in relation to the cytological findings. TABLE 1Clinical findings on veterinary ear examination, cytological results, bacterial diagnostic sampling and treatments for acute canine otitis externa in Sweden in 2024, presented per ear and in comparison to recommendations in national guidelines.Cytological resultTop 3 clinical findingsSampled for bacterial cultureTreatment with…Recommendations in national guidelines SwedenAntibioticsCorticosteroidsEar cleaningTopicalTopicalSystemicSystemicOverallOverallCytological Evaluation Performed (75%; 602/806)4% (23/602) 2% (10/602) 0% (0/602) 2% (10/602) 77% (463/602) 25% (153/602) 91% (546/602) 96% (575/602)Microbes without neutrophils (561/602) Malassezia and/or cocci (530/602) 81% erythema (430/530) 71% ceruminous discharge (375/530) 30% oedema (159/530) 1% (5/530) 2% (8/530) 0% (0/530) 2% (8/530) 78% (415/530) 23% (121/530) 90% (475/530) 95% (503/530) Topical antiseptics ± topical corticosteroids Rods a (31/602) 84% erythema (26/31) 61% purulent discharge (19/31) 39% oedema (12/31) 39% (12/31) 6% (2/31) 0% (0/31) 6% (2/31) 61% (19/31) 48% (15/31) 97% (30/31) 100% (31/31)Sampling for bacterial culture. Topical antiseptics (chlorhexidine) or TrisEDTA + topical antibiotic (if Pseudomonas spp. confirmed)Microbes and neutrophils (36/602) Malassezia and/or cocci (24/36) 92% erythema (22/24) 71% oedema (17/24) 63% ceruminous discharge (15/24) 8% (2/24) 0% (0/24) 0% (0/24) 0% (0/24) 79% (19/24) 33% (8/24) 100% (24/24) 100% (24/24) Topical antiseptics ± topical corticosteroids Rods a (12/36) 83% erythema (10/12) 75% purulent discharge (9/12) 58% oedema (7/12) 33% (4/12) 0% (0/12)0% (0/12) 0% (0/12) 67% (8/12) 50% (6/12) 100% (12/12) 100% (12/12)Sampling for bacterial culture. Topical antiseptics (chlorhexidine) or TrisEDTA + topical antibiotic (if Pseudomonas spp. confirmed)Neutrophils only (5/602) 100% erythema (5/5) 60% oedema (3/5) 40% ceruminous discharge (2/5) 0% (0/5) 0% (0/5) 0% (0/5) 0% (0/5) 40% (2/5) 60% (3/5) 100% (5/5) 100% (5/5)No microbes & no neutrophils (0/602)n/an/an/an/an/aNo cytological evaluation performed (25%; 204/806)0% (0/204) 0% (0/204) 1% (2/204) 1% (2/204) 38% (78/204) 8% (17/204) 43% (88/204) 45% (92/204) Note: The table presents the results for dogs with details for both ears (806 ears for Sweden). a Rods ± Malassezia and/or cocci. Clinical findings on veterinary ear examination, cytological results, bacterial diagnostic sampling and treatments for acute canine otitis externa in Sweden in 2024, presented per ear and in comparison to recommendations in national guidelines. 2% (10/602) 0% (0/602) 2% (10/602) 77% (463/602) 25% (153/602) 91% (546/602) 81% erythema (430/530) 71% ceruminous discharge (375/530) 30% oedema (159/530) 2% (8/530) 0% (0/530) 2% (8/530) 78% (415/530) 23% (121/530) 90% (475/530) Topical antiseptics ± topical corticosteroids 84% erythema (26/31) 61% purulent discharge (19/31) 39% oedema (12/31) 6% (2/31) 0% (0/31) 6% (2/31) 61% (19/31) 48% (15/31) 97% (30/31) 92% erythema (22/24) 71% oedema (17/24) 63% ceruminous discharge (15/24) 0% (0/24) 0% (0/24) 0% (0/24) 79% (19/24) 33% (8/24) 100% (24/24) Topical antiseptics ± topical corticosteroids 83% erythema (10/12) 75% purulent discharge (9/12) 58% oedema (7/12) 0% (0/12)0% (0/12) 0% (0/12) 67% (8/12) 50% (6/12) 100% (12/12) 100% erythema (5/5) 60% oedema (3/5) 40% ceruminous discharge (2/5) 0% (0/5) 0% (0/5) 0% (0/5) 40% (2/5) 60% (3/5) 100% (5/5) 0% (0/204) 1% (2/204) 1% (2/204) 38% (78/204) 8% (17/204) 43% (88/204) Note: The table presents the results for dogs with details for both ears (806 ears for Sweden). Rods ± Malassezia and/or cocci. TABLE 2Clinical findings on veterinary ear examination, cytological results, bacterial diagnostic sampling and treatments for acute canine otitis externa in Finland in 2024 presented per ear and in comparison to recommendations in national guidelines.Cytological resultTop 3 clinical findingsSampled for bacterial cultureTreatment with…Recommendations in national guidelines FinlandAntibioticsCorticosteroidsEar cleaningTopicalTopicalSystemicSystemicOverallOverallCytological evaluation performed (76%; 642/844)< 1% (2/642) 26% (165/642) 1% (6/642) 26% (169/642) 95% (611/642) 33% (209/642) 98% (627/642) 82% (528/642)Microbes without neutrophils (532/642) Malassezia and/or cocci (513/532) 76% erythema (389/513) 72% ceruminous discharge (367/513) 29% oedema (150/513) 0% (0/513) 16% (81/513) < 1% (2/513) 16% (81/513) 95% (486/513) 28% (144/513) 97% (499/513) 80% (412/513)Topical antiseptics + topical and/or systemic corticosteroidsRods a (19/532) 79% erythema (15/19) 58% ceruminous discharge (11/19) 47% oedema (9/19) 5% (1/19) 47% (9/19) 5% (1/19) 53% (10/19) 89% (17/19) 39% (7/19) 95% (18/19) 95% (18/19)Microbes and neutrophils (109/642) Malassezia and/or cocci (87/109) 89% erythema (77/87) 74% oedema (64/87) 56% purulent discharge (49/87) 0% (0/87) 67% (58/87) 0% (0/87) 67% (58/87) 100% (87/87) 51% (44/87) 100% (87/87) 90% (78/87)Topical antibiotics (fusidic acid and/or polymyxin B)Rods a (22/109) 91% purulent discharge (20/22) 86% erythema (19/22) 73% oedema (16/22) 5% (1/22) 77% (17/22) 14% (3/22) 91% (20/22) 91% (20/22) 64% (14/22) 100% (22/22) 86% (19/22)Neutrophils only (1/642) 100% erythema (1/1) 100% oedema (1/1) 100% ulceration (1/1) 100% purulent discharge (1/1) 0% (0/1) 0% (0/1) 0% (0/1) 0% (0/1) 100% (1/1) 0% (0/1) 100% (1/1) 100% (1/1)Topical and/or systemic corticosteroidsNo microbes & no neutrophils (0/642)n/an/an/an/an/aNo recommendationsNo cytological evaluation performed (24%; 202/844)0% (0/202) 1% (1/202) 0% (0/202) 1% (1/202) 26% (52/202) 16% (33/202) 36% (73/202) 30% (61/202)No recommendations Note: The table presents the results for dogs with details for both ears (844 ears for Finland). a Rods ± Malassezia and/or cocci. Clinical findings on veterinary ear examination, cytological results, bacterial diagnostic sampling and treatments for acute canine otitis externa in Finland in 2024 presented per ear and in comparison to recommendations in national guidelines. 26% (165/642) 1% (6/642) 26% (169/642) 95% (611/642) 33% (209/642) 98% (627/642) 76% erythema (389/513) 72% ceruminous discharge (367/513) 29% oedema (150/513) 16% (81/513) < 1% (2/513) 16% (81/513) 95% (486/513) 28% (144/513) 97% (499/513) 79% erythema (15/19) 58% ceruminous discharge (11/19) 47% oedema (9/19) 47% (9/19) 5% (1/19) 53% (10/19) 89% (17/19) 39% (7/19) 95% (18/19) 89% erythema (77/87) 74% oedema (64/87) 56% purulent discharge (49/87) 67% (58/87) 0% (0/87) 67% (58/87) 100% (87/87) 51% (44/87) 100% (87/87) 91% purulent discharge (20/22) 86% erythema (19/22) 73% oedema (16/22) 77% (17/22) 14% (3/22) 91% (20/22) 91% (20/22) 64% (14/22) 100% (22/22) 100% erythema (1/1) 100% oedema (1/1) 100% ulceration (1/1) 100% purulent discharge (1/1) 0% (0/1) 0% (0/1) 0% (0/1) 100% (1/1) 0% (0/1) 100% (1/1) 1% (1/202) 0% (0/202) 1% (1/202) 26% (52/202) 16% (33/202) 36% (73/202) Note: The table presents the results for dogs with details for both ears (844 ears for Finland). Rods ± Malassezia and/or cocci. TABLE 3Clinical findings on veterinary ear examination, cytological results, bacterial diagnostic sampling and treatments for acute canine otitis externa in Norway in 2024, presented per ear and in comparison to recommendations in national guidelines.Cytological resultTop 3 clinical findingsSampled for bacterial cultureTreatment with…Recommendations in national guidelines NorwayAntibioticsCorticosteroidsEar cleaningTopicalTopicalSystemicSystemicOverallOverallCytological evaluation performed (71%; 248/350)4% (9/248) 31% (76/248) 1% (2/248) 31% (76/248) 73% (181/248) 35% (88/248) 89% (221/248) 88% (219/248)Microbes without neutrophils (210/248) Malassezia and/or cocci (191/210) 86% erythema (164/191) 74% ceruminous discharge (142/191) 32% oedema (61/191) 0% (0/191) 28% (53/191) 1% (2/191) 28% (53/191) 74% (142/191) 31% (59/191) 86% (165/191) 88% (168/191)Topical antiseptics +/− topical corticosteroids (mild cases), or topical antibiotics (severe cases)Rods a (19/210) 89% erythema (17/19) 68% purulent discharge (13/19) 63% oedema (12/19) 32% (6/19) 37% (7/19) 0% (0/19) 37% (7/19) 63% (12/19) 53% (10/19) 95% (18/19) 100% (19/19) Topical antibiotics (Silver sulfadiazine + TrisEDTA (1), gentamycin (2), or polymyxin B (3)) Microbes and neutrophils (38/248) Malassezia and/or cocci (33/38) 100% erythema (33/33) 72% ceruminous discharge (24/33) 45% oedema (15/33) 0% (0/33) 39% (13/33) 0% (0/33) 39% (13/33) 76% (25/33) 42% (14/33) 100% (33/33) 88% (29/33)Topical antiseptics +/− topical corticosteroids (mild cases), or topical antibiotics (severe cases)Rods a (5/38) 100% erythema (5/5) 80% oedema (4/5) 80% ulcer (4/5) 60% (3/5) 60% (3/5) 0% (0/5) 60% (3/5) 40% (2/5) 100% (5/5) 100% (5/5) 60% (3/5) Topical antibiotics (Silver sulfadiazine + TrisEDTA (1), gentamycin (2), or polymyxin B (3)) Neutrophils only (0/248)n/an/an/an/an/aNo recommendationsNo microbes & no neutrophils (0/248)n/an/an/an/an/aNo recommendationsNo cytological evaluation performed (29%; 102/350)0% (0/102) 1% (1/102) 0% (0/102) 1% (1/102) 18% (18/102) 10% (10/102) 25% (25/102) 21% (21/102) Note: The table presents the results for dogs with details for both ears (350 ears for Norway). a Rods ± Malassezia and/or cocci. Clinical findings on veterinary ear examination, cytological results, bacterial diagnostic sampling and treatments for acute canine otitis externa in Norway in 2024, presented per ear and in comparison to recommendations in national guidelines. 31% (76/248) 1% (2/248) 31% (76/248) 73% (181/248) 35% (88/248) 89% (221/248) 86% erythema (164/191) 74% ceruminous discharge (142/191) 32% oedema (61/191) 28% (53/191) 1% (2/191) 28% (53/191) 74% (142/191) 31% (59/191) 86% (165/191) 89% erythema (17/19) 68% purulent discharge (13/19) 63% oedema (12/19) 37% (7/19) 0% (0/19) 37% (7/19) 63% (12/19) 53% (10/19) 95% (18/19) Topical antibiotics (Silver sulfadiazine + TrisEDTA (1), gentamycin (2), or polymyxin B (3)) 100% erythema (33/33) 72% ceruminous discharge (24/33) 45% oedema (15/33) 39% (13/33) 0% (0/33) 39% (13/33) 76% (25/33) 42% (14/33) 100% (33/33) 100% erythema (5/5) 80% oedema (4/5) 80% ulcer (4/5) 60% (3/5) 0% (0/5) 60% (3/5) 40% (2/5) 100% (5/5) 100% (5/5) Topical antibiotics (Silver sulfadiazine + TrisEDTA (1), gentamycin (2), or polymyxin B (3)) 1% (1/102) 0% (0/102) 1% (1/102) 18% (18/102) 10% (10/102) 25% (25/102) Note: The table presents the results for dogs with details for both ears (350 ears for Norway). Rods ± Malassezia and/or cocci. Cytological Findings Per Dog Analysis Overall, cytological findings were reported in 93% (983 of 1060) of the dogs. Corresponding percentages per country were 90% (382 of 423) for Sweden, 95% (422 of 446) for Finland and 94% (179 of 191) for Norway. Per Ear Analysis Regarding per ear analysis, cytological findings were reported for 1492 ears. The most common findings were Malassezia and/or coccoid bacteria without neutrophils or rods (83%; 1234 of 1492), with Malassezia as the sole finding being the most frequent (873 of 1234). Rods were found in 7% (108 of 1492) and neutrophils in 13% (189 of 1492) of ears. Figure 1 summarises the cytological findings for all ears and Tables 1, 2, 3 summarise the country‐specific findings. Cytological findings in per ear analysis (2000 ears). Bacterial Cultures Per Dog Analysis Overall, in approximately 3% (30 of 1060) of the dogs, bacterial culture was performed from at least one ear. The corresponding percentages per country were 5% (20 of 423) in Sweden, 1% (three of 446) in Finland and 4% (seven of 191) in Norway. Per Ear Analysis All of the ears sampled for bacterial culture had both clinical and cytological findings (n = 34). Detailed information can be found in Tables 1, 2, 3. Antibiotic Treatment Per Dog Analysis Of all the dogs in the study, 18% (190 of 1060) were treated with antibiotics. Antibiotic use was significantly higher in Norway (28%; 54 of 191) and Finland (29%; 128 of 446) than Sweden (2%; eight of 423; p < 0.001; Figure 2). Use of antibiotics and glucocorticoids (including polypharmaceutical products), as well as ear cleaners in dogs with acute otitis externa in three Nordic countries in 2024 (1060 dogs). The use of antibiotics was primarily topical, and the most frequently used topical antibiotic was polymyxin B (57%; 106 of 186), followed by fusidic acid in combination with aminoglycosides (18%; 34 of 186) and fluoroquinolones (12%; 22 of 186). The choice of topical antibiotic substances in terms of EMA classification differed between countries (p = 0.013; Table 4). TABLE 4Choice of antibiotic substances in dogs receiving topical treatment for otitis externa in three Nordic countries.Antibiotic substance (per dog)NorwayFinlandSwedenAll countriesEMA class B33 (61%)93 (74%)2 (29%)128 (69%)Quinolones0 (0%)22 (18%)0 (0%)22 (12%)Polymyxins B33 (61%)71 (57%)2 (29%)106 (57%)EMA class C21 (39%)32 (26%)5 (71%)58 (31%)Fusidic acid (D) + aminoglycosides (C)6 (11%)26 (21%)2 (29%)34 (18%)Aminoglycosides6 (11%)5 (4%)2 (29%)13 (7%)Amphenicoles9 (17%)1 (1%)1 (14%)11 (6%)Overall541257186 Choice of antibiotic substances in dogs receiving topical treatment for otitis externa in three Nordic countries. Less than 1% (six of 1060) of the dogs received systemic antibiotics with COE as the indication for treatment. Five dogs were treated with amoxicillin/clavulanic acid (EMA category C), four in Finland and one in Norway, and one dog in Sweden was treated with amoxicillin (EMA category D). Two dogs received both systemic and topical antibiotic treatment. Per Ear Analysis In total, 259 ears were treated with antibiotics. All of these had reported clinical and/or cytological findings on veterinary examination: 253 with one or more clinical findings and 255 with cytological findings reported. Analysing the ears with clinical findings, 38% (104 of 272) of ears with purulent discharge, 33% (57 of 171) of ears with ulceration, 25% (143 of 571) of ears with oedema, 16% (228 of 1349) of ears with erythema and 13% (144 of 1101) of ears with ceruminous discharge received antibiotics. Scrutinising antibiotic use based on cytological findings, antibiotics were administered in 12% (142 of 1243) of ears with Malassezia and/or coccoid bacteria and in 28% (19 of 69) of ears with rod‐shaped bacteria. The use of antibiotics was significantly higher when neutrophils were present: 49% (71 of 144) in ears with neutrophils and Malassezia and/or coccoid bacteria, and 59% (23 of 39) in ears with neutrophils and rod‐shaped bacteria. Country‐specific data are presented in Tables 1, 2, 3. Although antibiotic use differed among the three countries in relation to the clinical and cytological findings, the regression model demonstrated no statistically significant interactions. Instead, the strongest predictor of antibiotic use was country alone, with dogs in Finland and Norway significantly more likely to be treated with antibiotics than those in Sweden (p < 0.001). The second most notable association with antibiotic use was cytological findings of neutrophils and rods (p < 0.001; Table 5), irrespective of country. TABLE 5Logistic regression model with factors related to antibiotic use (topical and/or systemic) in acute canine otitis externa in three Nordic countries.Independent variablesOR95% CI p CountrySwedenRefFinland23.211.6–46.5< 0.001Norway19.410.0–37.4< 0.001Clinical findings a Oedema1.71.3–2.40.001Ulceration1.81.2–2.80.007Purulent discharge2.41.7–3.5< 0.001Cytological findingsNo neutrophils with or without microbesRefMicrobes and neutrophils Malassezia 2.91.8–4.6< 0.001Cocci4.62.1–10.4< 0.001Rods5.82.4–13.9< 0.001Constant0.0080.004–0.02< 0.001Abbreviations: CI, confidence interval; OR, odds ratio; Ref, reference level. a Dichotomous variable with “no” as ref. Logistic regression model with factors related to antibiotic use (topical and/or systemic) in acute canine otitis externa in three Nordic countries. Abbreviations: CI, confidence interval; OR, odds ratio; Ref, reference level. Dichotomous variable with “no” as ref. Glucocorticoid Treatment Per Dog Analysis The overall use of glucocorticoids for dogs with acute COE was 94% (997 of 1060). Glucocorticoid use was significantly higher in Finland (99%; 443 of 446) compared to both Norway (93%; 177 of 191; p < 0.001) and Sweden (89%; 377 of 423; p < 0.001; Figure 2), whilst the difference observed between Norway and Sweden was not significant (p = 0.17; Figure 2). The majority of dogs (64%; 682 of 1060) were treated with topical glucocorticoids alone, while 21% (224 of 1060) received systemic glucocorticoids in conjunction with topical treatment and 9% (91 of 1060) were treated with systemic glucocorticoids alone. In Finland and Norway, 29% (125 of 437) and 37% (53 of 143) of the total topical glucocorticoid use per dog was represented by the use of polypharmacy products compared to 2% (seven of 326) in Sweden. Per Ear Analysis Tables 1, 2, 3 provide country‐specific details of glucocorticoid treatment and different cytological findings per ear. Treatment With Ear Cleaners Per Dog Analysis Treatment with ear cleaners per dog, either at the clinic or at home, was significantly higher in Sweden (96%; 404 of 423) compared to both Finland (84%; 373 of 446; p < 0.001) and Norway (88%; 168 of 191; p = 0.001), whilst Finland and Norway did not significantly differ (p = 0.16, Figure 2). For all three countries combined, the corresponding figure was 89% (945 of 1060). Overall, 6% (58 of 1060) of the dogs were treated with ear cleaners without combining this with glucocorticoids and/or antibiotics: 10% (42 of 423) in Sweden, < 1% (two of 446) in Finland and 7% (14 of 191) in Norway. Per Ear Analysis Tables 1, 2, 3 provide details of topical antiseptic treatment per ear and per cytological result. Discussion In this study, 18% of the dogs with acute COE were treated with antibiotics, predominantly via topical administration. Marked intercountry variation in practices was observed, with a significantly lower prevalence of antibiotic use in Sweden (2%) than in Finland (29%) and Norway (28%). Systemic antibiotic administration was reported in < 1% of cases. Cytological evaluation was performed in 94% of the dogs, and cytological findings predicted antibiotic use more than clinical findings, especially when neutrophils with rod‐shaped bacteria were reported. However, among all variables assessed, country remained the strongest predictive variable for antibiotic use. In all three Nordic countries, the most common management of acute COE was a non‐antibiotic treatment regimen with a combination of ear cleaning and glucocorticoids. To the best of our knowledge, this is the first publication available on the frequency of antibiotic use in acute COE. However, COE is likely to be a common reason for initiating antibiotic therapy, as it is one of the most frequently diagnosed conditions in dogs in primary veterinary care [9, 13, 14, 15, 16]. Our study revealed a very low use of systemic antibiotics for COE. This is notable because systemic therapy often provides much lower concentrations in the ear canal compared to topical administration [2]. Furthermore, the systemic use of antibiotics exerts higher selective pressure for resistance development [12]. Nevertheless, topical antibiotics also may promote the emergence of resistant bacteria, and the occurrence of multidrug‐resistant bacteria in cultures from dogs with COE has been reported to be as high as 12%–57% [22, 23]. Findings from France suggest that promoting responsible antibiotic use in COE can reduce resistance levels, underscoring the importance of minimising avoidable antibiotic use in this context [22]. Furthermore, a recent study demonstrated that most dogs with erythroceruminous COE can be managed without antibiotics [24]. In our study, there was a strong association between antibiotic use and reported cytological findings of neutrophils and microbes (potentially indicative of suppurative COE). However, a noteworthy proportion of the antibiotic use in Finland and Norway was for erythematous ears without findings of neutrophils (probably representing erythroceruminous COE cases). The difference in antibiotic use between countries may be caused by several factors, such as variations in guidelines, adherence to and dissemination of recommendations, traditions and overall awareness of antimicrobial resistance [6, 7, 8, 25, 26]. Additionally, the choice of using polypharmaceutical products containing antibiotics may have been influenced by their antifungal properties, as Malassezia was the most common cytological finding. However, our study did not allow further analyses in this regard. In 2019, EMA updated its categorisation of antibiotics used for animals, with categories ranging from A to D. When antibiotics are needed, the substance used should be as far from category A as possible [12]. This categorisation applies to both systemic and topical antibiotics, even though systemic treatments are considered to have a greater impact on resistance development. In our study, the most commonly used antibiotics in Finland and Norway were topical polymyxin B and fluoroquinolones, which both belong to EMA category B. For the few cases in Sweden in which antibiotics were used, these mostly belonged to EMA category C. Polymyxin B is currently recommended as a first‐line topical antibiotic in the national guidelines of both Finland and Norway, and not in Sweden [6, 7, 8]. This indicates that national guidelines appear to have influenced veterinary surgeons' decision‐making more than EMA restrictions, which aligns with a previous study reporting national guidelines having an impact on antibiotic use patterns [27]. Such considerations highlight the need for regular updates to guidelines, ensuring alignment with relevant legislation and international recommendations. As the veterinary surgeons participating in this survey were not restricted in their choice of antibiotic substances (either by the corporate group or by national regulatory differences), other factors similar to those influencing overall antibiotic use are more likely to explain the differences observed [6, 7, 8, 25, 26]. The overall use of glucocorticoids per dog across all three countries was high (94%). This was not surprising considering their well‐known anti‐inflammatory effect, and probably also reflects the homogeneity of the different national guidelines in this regard [6, 7, 8, 28]. Finland had the highest rate of glucocorticoid use (99%), which might reflect the minor differences between the three national guidelines in this sense [6, 7, 8]. Furthermore, the use of topical glucocorticoids in Finland and Norway was to a greater extent represented by poly‐pharmaceutical ear drops compared to Sweden. The primary motivation for using poly‐pharmaceutical products for COE was not investigated in this study, yet it could be a focus for future research. As for corticosteroids, ear cleaners are recommended for most COE cases in the national guidelines of all three countries [6, 7, 8]. The use of ear cleaners per dog was high in all the countries (89%), yet was highest in Sweden. Interestingly, 10% of Swedish dogs and 7% of Norwegian dogs received ear cleaners without glucocorticoids or antibiotics. Ear cleaning has many benefits, ranging from antibacterial effects to mechanical cleaning, yet it also can potentially worsen the COE if used inappropriately [9, 29]. In our study, we performed no further analysis on the use of ear cleaners or intercountry differences. When aiming at reducing the unnecessary use of antibiotics in COE, studies on the optimal use of ear cleaners alone or in combination with glucocorticoids are highly warranted. Nearly half of the dogs in our cohort had a reported history of COE, yet < 10% were receiving ongoing treatment for dermatological disorders. However, information regarding the frequency of recurrence and the time since the last episode of otitis was not available in our data. Nevertheless, in recurrent otitis, addressing underlying causes and factors is essential to preventing recurrence and thus represents a key factor in reducing antimicrobial use [2]. Our study has several strengths. It encompassed a large cohort with detailed information and analysis regarding patient history, clinical findings, diagnostic methods and treatments for acute COE in three countries. It enabled comparisons between antibiotic use and several different clinical factors. Additionally, our cohort included a variety of practice sizes and characteristics in all of the participating countries, spanning from first‐opinion practices to referral animal hospitals, which should increase the generalisability of our results to the wider population. There are some limitations to our study. This was an observational cross‐sectional study, and certain limitations are intrinsic to the study design, such as no possibility for analysing treatment outcomes or the long‐term management of COE. Furthermore, as with other observational studies based on surveys, our study also included a risk of research participation effects, which could have affected the level of diagnostics performed and treatment choices. Our study design also could have involved a risk of selection bias, which in our study mainly concerned which veterinary practices participated and which cases were excluded or not from the survey. The definition of acute COE varies [3, 30, 31]. In our survey, cases were classified as acute based on an owner‐reported duration of ≤ 4 weeks, which may have allowed some longer standing cases to be included if early signs were not recognised. Although veterinary surgeons were instructed to exclude signs of chronicity, some misclassification cannot be ruled out. Furthermore, all practices in the survey belonged to the same corporate group, which may limit the generalisability of the findings. Nonetheless, there were no company‐standardised procedures for COE management or restrictions on antibiotic substance accessibility. Another limitation is associated with uncertainty concerning both the indication for and the selection of topical therapy, particularly when using polypharmaceutical products. The choice of using these types of products may have been based on the presence of bacteria, or they may have been used as an antifungal treatment. The selection also may have been influenced by the degree of inflammation and the type of steroid contained in these preparations. It is important, too, to acknowledge that the reliability of the clinical and cytological findings is affected by the fact that examinations, sample collection and interpretations were performed by multiple veterinary surgeons with varying levels of experience. Additionally, neither the clinical findings nor the cytological findings were recorded in a standardised and quantitative manner. We included all recorded clinical and cytological findings from 1000 dogs with details from both ears into per ear statistics, as it was not always retrospectively clear whether cases were truly uni‐ or bilateral. Therefore, some findings may have originated from clinically normal ears, as, for example, small numbers of bacteria and yeast also may be present in normal ear cytological results. It also is possible that some information on clinical and cytological findings was missing, as some veterinary surgeons had incompletely responded to the survey. Nevertheless, the number of such ears is likely to have been small and therefore unlikely to have influenced the results. Despite these limitations, the per‐ear analysis provides relevant additional information on the variation in clinical and cytological findings and their association with antibiotic use for COE in these three countries. This study provides insights into antibiotic use in the treatment of acute COE within a large veterinary corporate across three Nordic countries. Although the overall treatment approaches were broadly similar, notable differences were identified. Given the high prevalence of COE, optimising both antibiotic and non‐antibiotic treatment strategies in these cases has the potential to influence overall antibiotic use. Further research on treatment outcomes across different COE types, particularly when underlying causes are concurrently addressed, is warranted. Such studies could support more prudent antibiotic use and provide more precise, outcome‐driven treatment recommendations for COE. Conclusions In this study, most acute COE cases in Sweden, Finland and Norway were treated with glucocorticoids and ear cleaners without the use of antibiotics. Swedish practices stood out with a very low antibiotic use of 2%, while in Finland and Norway, almost 30% of the dogs in our survey received topical antibiotics. Our results provide valuable information from three Nordic countries, inspiring future antibiotic stewardship efforts. Author Contributions Ditte Ljungquist: writing – review and editing, writing – original draft, conceptualization, methodology, project administration, data curation, formal analysis. Riitta Seppänen: conceptualization, methodology, writing – review and editing. Kaisa Saarinen: writing – original draft, writing – review and editing, conceptualization, methodology, project administration, data curation. Mirja Kaimio: conceptualization, methodology, writing – review and editing. Anna‐Maria Andersson: conceptualization, methodology, project administration, data curation, formal analysis, writing – review and editing. Funding This work was supported by IVC Evidensia. Conflicts of Interest The authors declare no conflicts of interest. Supporting information Data S1: vde70094‐sup‐0001‐Supinfo1.pdf.